Novartis India Limited has submitted its investor presentation detailing the operational strategies and business roadmap for its pharmaceutical platform.

The update highlights the multi-decade heritage and established prescriber equity of flagship brands like Voveran, Methergin, Calcium-Sandoz, and Tegrital, which maintain leadership positions across priority therapeutic areas.

The company's strategic focus centers on establishing a dedicated field force to drive direct prescriber engagement, expanding its presence in chronic therapies, and executing disciplined capital deployment.

Shareholders are informed about the transition toward direct brand promotion and distribution control to unlock the untapped potential of its mature portfolio.